

Originalarbeiten:

1. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efsthathiou E, Oudard S, Morris MJ, Sizer B, **Goebell PJ**, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ. (2013) Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. *Lancet Oncol.*: S1470-2045(13)70479-0.
2. Kunath F, Krause SF, Wullich B, **Goebell PJ**, Engehausen DG, Burger M, Meerpohl JJ, Keck B. (2013) Bladder cancer - the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register clinicaltrials.gov. *BMC Urol.* 13:56.
3. Rogler A, Hoja S, Socher E, Nolte E, Wach S, Wieland W, Hofstädter F, **Goebell PJ**, Wullich B, Hartmann A, Stoehr R (2013) Role of two single nucleotide polymorphisms in secreted frizzled related protein 1 and bladder cancer risk. *Int J Clin Exp Pathol.* 6:1984-98.
4. Schrader AJ, Seseke S, Keil C, Herrmann E, **Goebell PJ**, Weikert S, Steffens S, Bergmann L, Roigas J, Steiner T (2013) Temsirolimus in Daily Use: Results of a Prospective Multicentre Noninterventional Study of Patients with Metastatic Kidney Cancer. *Eur Urol.*
5. Keck B, Wach S, **Goebell PJ**, Kunath F, Bertz S, Lehmann J, Stöckle M, Taubert H, Wullich B, Hartmann A (2013) SNAI1 Protein Expression is an Independent Negative Prognosticator in Muscle-Invasive Bladder Cancer. *Ann Surg Oncol.*
6. Bergmann L, **Goebell PJ**, Kube U, Kindler M, Herrmann E, Janssen J, Schmitz J, Weikert S, Steiner G, Jakob A, Staehler M (2013) Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFR-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study. *Onkologie* 36:95-100.
7. Richterstetter M, Wullich B, Amann K, Haeberle L, Engehausen DG, **Goebell PJ**, Krause FS (2012) The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. *BJU Int.* 10:76-9.
8. Keck B, Giedl J, Kunath F, **Goebell PJ**, Engehausen DG, Hartmann A, Wullich B (2012) Clinical Course of Plasmacytoid Urothelial Carcinoma of the Upper Urinary Tract: A Case Report. *Urol Int.* 89:120-2.
9. Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; **REACT Study Group** (2012) An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. *Eur J Cancer* 48:324-32.
10. **Goebell PJ**, Groshen SG, Schmitz-Dräger BJ and the Members of the International Study Initiative on Bladder Cancer (ISBC) (2010) P53 Immunohistochemistry in Bladder cancer – new approaches to an old story. *Urologic Oncology: Seminars and Original Investigations* 28:377-88.

11. **Goebell PJ**, Morente MM (2010) New concepts of biobanks – Strategic chance for uro-oncology. *Urologic Oncology: Seminars and Original Investigations* 28:449-57.
12. Keck B, Rau T, Krause FS, Walter B, **Goebell PJ**, Hartmann A, Wullich B (2010) Diagnostic challenge of atypical colorectal metastasis to the renal pelvis. *Int J Colorectal Dis* 25:1387.
13. Fritsche HM, Burger M, Denzinger S, Legal W, **Goebell PJ**, Hartmann A (2008) Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases. *J Urol* 180:1923-7.
14. **Goebell PJ**, Groshen S, Schmitz-Dräger BJ (2008) Guidelines for development of diagnostic markers in bladder cancer. *World J Urol.* 26:5-11.
15. Keck B, Stöhr R, **Goebell PJ**, Fritsche HM, Wullich B, Hartmann A (2008) Das plasmacytoide Urothelkarzinom. *Pathologie* 29:379-82.
16. Siemer S, Van Poppel H, Lahme S, Altziebler S, Machtens S, Strohmaier W, Wechsel HW, **Goebell PJ**, Schmeller N, Oberneder R, Stolzenburg JU, Becker H, Lüftenegger W, Tetens V, Joniau S (2007) Kidney tumour resection with use of tacho-sil as haemostatic treatment. *Eur Urol.* 52:1156-63.
17. Rose A, Suttor S, **Goebell PJ**, Rossi R, Rübber H (2007) Transurethral resection of bladder tumors and prostate enlargement in physiological saline solution (TURIS): A prospective study. *Urologe A* 46:1148-50.
18. Oosterlinck W, Solsona E, Akaza H, Busch C, **Goebell PJ**, Malmstrom PU, Ozen H, Sved P (2005) Low-grade Ta (noninvasive) urothelial carcinoma of the bladder. *Urology* 66 S:75-89.
19. Habuchi T, Marberger M, Droller MJ, Hemstreet GP 3rd, Grossman HB, Schalken JA, Schmitz-Dräger BJ, Murphy WM, Bono AV, **Goebell PJ**, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB (2005) Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. *Urology* 66 S:64-74.
20. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, Bono AV, Getzenberg RH, **Goebell PJ**, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ (2005) Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. *Urology* 66 S:35-63.
21. **Goebell PJ**, Groshen S, Schmitz-Dräger BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Grossman HB, Dinney CPN, Waldman F, Cote RJ (2005) Concepts for banking tissue in urologic oncology - The International Bladder Cancer Bank. *Clin Cancer Res.* 11:413-5.
22. Schlatt S, Honaramooz A, Ehmcke J, **Goebell PJ**, Dhir R, Dobrinski I, Rübber H, Patrizio P (2005) Limited survival of adult human testicular tissue as ectopic xenograft. *Hum Reprod.* 21:384-9.
23. **The Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration** (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. *Eur Urol.* 48:202-6.

24. **The Advanced Bladder Cancer (ABC) Meta-analysis Collaboration** (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. *Eur Urol.* 48:189-201.
25. Chatterjee SJ, George B, **Goebell PJ**, Alavi-Tafreshi M, Shi SR, Fung YK, Jones PA, Cordon-Cardo C, Datar RH, Cote RJ (2004) Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. *J Pathol.* 203:762-70.
26. Chatterjee SJ, Datar R, Youssefzadeh D, George B, **Goebell PJ**, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ (2004) Combined Effects of p53, p21, and pRb Expression in the Progression of Bladder Transitional Cell Carcinoma. *J Clin Oncol.* 22:1007-13.
27. **Goebell PJ**, Groshen S, Schmitz-Dräger BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Grossman HB, Waldman F, Cote RJ (2004) The International Bladder Cancer Bank – proposal for a new study concept. *Urologic Oncology: Seminars and Original Investigations* 22:277-84.
28. Abol-Enein H, Bassi PF, Bono AV, Boyer M, Clarke NW, Coppin CML, Cortesi E, **Goebell PJ**, Groshen S, Hall RR, Horwich A, Malmström P-U, Martinez-Piñeiro JA, Parmar MKB, Raghavan D, Roberts JT, Sengeløv L, Sherif A, Stewart LA, Stockle M, Sylvester R, Tierney JF, Torti FM, Vale C, Wallace DMA, Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. *Lancet* 361:1927-34.
29. Otto T, Suhr J, Krege S, **Goebell PJ**, Wishahi M, Bier UW, Rübber H (2002) Surgical Treatment of disseminated peritoneal metastases from urological cancer: results from a prospective study. *BJU Int.* 90:823-7.
30. **Goebell PJ**, Otto T, Suhr J and Rübber H (2002) Evaluation of an unconventional therapy with Mistletoelectin to prevent recurrence in the treatment of superficial bladder cancer - a randomized Phase II trial. *J Urol.* 168:72-5.
31. Luboldt HJ, Otto T, Suhr J, **Goebell PJ**, Krege S, Rübber H (2002) Komplementärmedizin des Harnblasenkarzinoms. Ergebnisse der Studiengruppe des Westdeutschen Tumorzentrums. *Urologe B* 42:293-6.
32. Jankevicius F, **Goebell PJ**, Kushima M, Schulz WA, Ackermann R, Schmitz-Dräger BJ (2002) p21 and p53 immunostaining and survival following Systemic Chemotherapy for Urothelial Cancer. *Urol. Int.* 69:174-80.
33. Otto T, Lümmen G, Bex A, Suhr J, **Goebell PJ**, Raz A, Rübber H (2002) Tumor cell motility: a novel target in cancer - experimental and clinical results. *Onkologie* 25:172-7.
34. Schmitz-Dräger BJ, **Goebell PJ**, Heydthausen M, The International Study Initiative on Bladder Cancer (ISBC) (2000) p53 Immunohistochemistry in bladder cancer: combined analysis: a way to go? *Urol Oncol*, 5:204-10.
35. Schmitz-Dräger BJ, **Goebell PJ**, Ebert T, Fradet Y (2000) P53 Immunohistochemistry as a Prognostic Marker in Bladder Cancer: Playground for Urology Scientists? *Eur Urol*, 38:691-700.
36. Franke KH, Miklosi M, **Goebell PJ**, Clasen S, Steinhoff C, Anastasiadis AG, Gerharz C-D, Schulz

- WA (2000) Cyclin-dependent kinase inhibitor p27^{KIP1} is expressed preferentially in early stages of urothelial carcinoma. *Urology*, 56:689-95.
37. Schulz WA, Jankevicius F, van Roeyen C, Gerharz CD, Kushima M, Bültel H, **Goebell P**, Schmitz-Dräger BJ (1998) Predictive value of molecular alterations for the prognosis of urothelial carcinoma. *Cancer Detect Prev* 22:422-9.
38. Schmitz-Dräger BJ, Kushima M, **Goebell P**, Jax TW, Gerharz CD, Bültel H, Schulz WA, Ebert T, Ackermann R (1997) p53 and MDM2 in the development and progression of bladder cancer. *Eur Urol* 32:487-93.

Übersichtsarbeiten:

1. Burger M, **Goebell PJ** (2012) Bladder cancer: Validity of the 2004 system for grading Ta bladder cancer. *Nat Rev Urol*. 14;9:126-7. (IF: 4,415; cited 0)
2. Meir K, Gaffney E, Simeon-Dubach D, Ravid R, Watson PH, Schacter B, Morente MM and Marble Arch International Working Group on Biobanking for Biomedical Research: Bjugn R, Clark B, de Blasio P, Carpenter J, Deschenes M, Devereux L, Dhir R, Gaffney E, **Goebell PJ**, Grizzle W, Hainaut P, Meir K, Mes-Masson AM, Miranda L, Morente MM, Parry-Jones A, Ravid R, Riegman P, Casali-Da-Rocha JC, Schacter B, Simeon-Dubach D, Fernando Soares F, Vaught J, Watson P, Zeps N (2011) The human face of Biobank Networks for Translational Research. *Biopreserv. Biobank* 9:279-85.
3. Grossman HB, Dinney CPN, Schmitz-Dräger BJ and **Goebell PJ** (2010) The International Bladder Cancer Network. *Urologic Oncology: Seminars and Original Investigations* 28:375-6.
4. **Goebell PJ**, Knowles M (2010) Bladder Cancer or Bladder Cancers? – genetically distinct malignant conditions of the urothelium. *Urologic Oncology: Seminars and Original Investigations* 28:409-28.
5. **Goebell PJ**, Keck B, Wach S, Wullich B (2010) Stellenwert von Biomarkern in der Urologie. *Urologe A* 49:547-59.
6. Shariat SF, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Dräger BJ, **Goebell PJ**, Malats N (2010) Statistical consideration for clinical biomarker research in bladder cancer. *Urologic Oncology: Seminars and Original Investigations* 28:389-400.
7. **Goebell PJ** (2009) Outcomes and response to therapy in bladder cancer – are biomarkers of any help? *Minerva Urol Nefrol*. 61:91-107.
8. Riegman PH, Morente MM, Betsou F, de Blasio P, Geary P; Marble Arch International Working Group on Biobanking for Biomedical Research: Betsou F, Bjugn R, Clark B, Botling J, Deblasio P, Deschenes M, Dhir R, Fore I, Gaffney E, Geary P, **Goebell PJ**, Grizzle W, Hainaut P, Hair J, Hewitt R, Meir K, Mes-Masson AM, Miranda L, Morente M, Parry-Jones A, Passiukov A, Riegman P, Casali Da Rocha JC, Simeon-Dubach D, Soares F, Thomas G, Vaught J, Zeps N (2008) Biobanking for better healthcare. *Mol Oncol*. 2:213-22.

9. **Goebell PJ**, Wullich B (2008) Age-adjusted prostate-specific antigen and prostate-specific antigen velocity cut points in prostate cancer screening. *Strahlentherapie und Onkologie* 5:283-4.
10. **Goebell PJ**, Legal W, Weiss C, Fietkau R, Wullich B, Krause FS (2008) Multimodale Therapien zum Blasenerhalt bei high grade Blasen Tumoren. *Urologe A* 47:838-45.
11. Vom Dorp F, Börgermann C, **Goebell PJ**, Schmid K, Siffert W, Rettenmeier AW, Rübben H (2007) Harnblasentumorregister. *Urologe A* 46:1139-40.
12. **Goebell PJ**, Rübben H, Müller G, Rettenmeier AW (2007) Das „Forum Proteomics“ am Universitätsklinikum Essen. *Urologe A* 46:1157-60.
13. Golka K, Rettenmeier AW, **Goebell PJ** (2007) Harnblasenkarzinom - Ursachen und Möglichkeiten der Vermeidung. *Onkologie* 13:449-58.
14. Golka K, **Goebell PJ**, Rettenmeier AW (2007) Ätiologie und Prävention des Harnblasenkarzinoms. *Dtsch Arztebl.* 104:719–23.
15. Bono AV, **Goebell PJ**, Groshen S, Lehmann J, Studer U, Torti FM, Abol-Enein H, Bassi P, Boyer M, Coppin CML, Cortesi E, Hall R, Horwich A, Malmstrom PU, Martinez-Pineiro JA, Sengelov L, Sherif A, Wallace DMA, Clarke NW, Roberts JT, Sylvester R, Parmar MKB, Stewart LA, Tierney JF, Vale CL (2006) Adjuvant chemotherapy for invasive bladder cancer (individual patient data). *Cochrane Database Syst Rev.* 2:CD006018.
16. **Goebell PJ**, vom Dorp F, Rödel C, Frohneberg D, Thüroff JW, Jocham D, Stief C, Roth S, Knüchel R, Schmidt KW, Kausch I, Zaak D, Wiesner C, Miller K, Sauer R, Rübben H (2006) Nicht-invasives und invasives Harnblasenkarzinom - Diagnostik und Therapie. *Urologe A* 45:873-886.
17. **Goebell PJ**, vom Dorp F, Rübben H (2006) Stellenwert der systemischen Chemotherapie im Harnblasenkarzinom. *Urologe A.* 45:586-593.
18. Golka K, Rettenmeier AW, **Goebell PJ** (2006) Harnblasenkarzinom - Ursachen und Möglichkeiten der Vermeidung. *Urologe A.* 45:361-368.
19. Abol-Enein H, Bassi P, Boyer M, Coppin CML, Cortesi E, Grossman HB, Hall RR, Horwich A, Malmstrom PU, Martinez-Pineiro JA, Sengelov L, Sherif A, Wallace DMA, Bono AV, **Goebell PJ**, Groshen S, Stockle FMTM, Studer U, Clarke NW, Raghavan D, Roberts JT, Sylvester R, Parmar MKB, Stewart LA, Tierney JF, Vale CL (2005) Neoadjuvant chemotherapy for invasive bladder cancer. *Cochrane Database Syst Rev.* 2:CD005246.
20. **Goebell PJ**, Villanueva CM, Rettenmeier AW, Rübben H, Kogevinas M (2003) Environmental exposure, chlorinated drinking water, and bladder cancer. *World J Urol.* 21:424-32.
21. Otto T, **Goebell PJ**, Rübben H (2003) Perioperative Chemotherapy in Advanced Bladder Cancer: Part II Adjuvant Treatment. *Onkologie* 26:484-8.
22. **Goebell PJ**, Otto T, Rübben H (2003) Perioperative Chemotherapy in Advanced Bladder Cancer: Part I Neoadjuvant Treatment. *Onkologie* 26:361-5.

23. Suhr J, **Goebell PJ**, Schmid KW, Worm K, Rübben H, Otto T (2002) Microarrays in der Urologie - Möglichkeiten in Forschung und Diagnostik. Akt Urol 33:262-7.

Weitere Publikationen und Buchbeiträge:

1. **Goebell PJ** (2011) Systemische Therapie des kastrationsresistenten Prostatakarzinoms – Eine Standort-Bestimmung in 2011. Journal Onkologie 5: 26-30.
2. vom Dorp F, **Goebell PJ**, Rödel C, Gschwend J, Stöckle M, Rübben H (2009) Therapie des muskelinvasiven Urothelkarzinoms der Harnblase. In: Rübben H (Hrsg.), Uroonkologie, 5. Auflage, Springer Medizin Verlag Heidelberg.
3. Betsou F, Luzergues A, Carter A, Geary P, Riegman PH, Clark B, Morente MM, Vaught J, Dhirr R, Druez-Vérité C, and the Marble Arch International Working Group on Biobanking for Biomedical Research: Betsou F, Bjugn R, Casali da Rocha JC, Clark B, Deblasio P, Deschenes M, Devereux M, Dhirr R, Fore I, Gaffney E, Geary P, **Goebell PJ**, Grizzle W, Hainaut P, Hair J, Hewitt R, Miranda L, Morente M, Parry-Jones A, Passiukov A, Riegman P, Simeon-Dubach D, Soares F, Thomas G, Vaught J, Watson P, Zeps N (2008) Towards Norms for Accreditation of Biobanks for Human Health and Medical Research: Compilation of Existing Guidelines into an ISO Certification/Accreditation Norm-Compatible Format. Quality Assur. J 11:221-294.
4. **Goebell PJ**, Sauer R, Rödel C, Rübben H (2007) Therapie des muskelinvasiven Urothelkarzinoms der Harnblase. In: Rübben H (Hrsg.), Uroonkologie, 4. Auflage, Springer Medizin Verlag Heidelberg.
5. **Goebell PJ**, Rübben H (2006) Urologische Notfälle. In: Rudofsky G, Schmaltz AA und Taeger K (Hrsg.) Ärztliche Sofortmaßnahmen, Elsevier, München.
6. Siemer S, Van Poppel H, Lahme S, Altziebler S, Machtens S, Strohmaier W, Wechsel HW, **Goebell PJ**, Schmeller N, Oberneder R, Stolzenburg JU, Becker H, Lüftenegger W, Tetens V (2006) Effektivität von TachoSil® als Hämostyptikum nach Nierenteilresektion. MedReview 11:7-8.
7. **Goebell PJ**, Rübben H, Müller G, Rettenmeier AW (2006) Das „Forum Proteomics“ am Universitätsklinikum Essen. In: Jahrbuch des Westdeutschen Tumorzentrum Essen, Typoteam Verlag, Essen.
8. Akaza H, Bush C, **Goebell PJ**, Malmström P-U, Oosterlinck W, Ozen H, Solsona E, Sved P (2006) Low Grade, Ta (Noninvasive) Urothelial Carcinoma of the Bladder. In: Soloway M, Carmack A, Khoury S (Eds.) SIU Monograph: Bladder Tumors. Health Publications Ltd., Paris, 139-64.
9. Lokeshwar VB, Habuchi T, Grossman HB, Murphy W, Hautmann SH, Hemstreet III GP, Bono AV, Getzenberg RH, **Goebell PJ**, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ (2006) Cytology and Tumor Markers: Tumor Markers beyond Cytology. In: Soloway M, Carmack A, Khoury S (Eds.) SIU Monograph: Bladder Tumors. Health Publications Ltd., Paris, 65-138.

10. **Goebell PJ**, Rübben H (2004) Rudolf Goebell and his contribution to the surgical management of female stress urinary incontinence. *AUANews* 9:17-8.
11. Otto J, **Goebell PJ**, Otto T (2004) Urologischer Notfall in der Onkologie. *Der Onkologe* 10:351-7.
12. Otto T, Lümme G, Bex A, Suhr J, **Goebell PJ**, Raz A, Rübben H (2003) Cell motility: a novel therapeutic target in cancer. In: *Research Advances in Cancer* 3:21-8.
13. **Goebell PJ** (2003) P53-Positivität weist auf Progression hin. *Urologische Nachrichten* 9:14.
14. Otto T, Suhr S, **Goebell PJ**, Krege S, Rübben H (2002) Komplementärmedizin des Harnblasenkarzinoms. In: *Jahrbuch des Westdeutschen Tumorzentrums Essen*, Typoteam Verlag, Essen.
15. **Goebell PJ**, Otto T, Rübben H, Müller G, Rettenmeier AW (2002) Neue massenspektrometrische Verfahren zur Aufklärung der Proteinfunktion in der Tumorforschung. In: *Jahrbuch des Westdeutschen Tumorzentrums Essen*, Typoteam Verlag, Essen.
16. Jankevicius F, **Goebell P**, Kushima M, Schulz WA, Ackermann R, Schmitz-Dräger B (2002) The value of p21 and p53 overexpression in predicting the outcome after systemic chemotherapy of urothelial cancer. *Acta Medica Lituanica* 9:27-33.
17. **Goebell PJ**, Suhr J, Wiggen-Kremer A, Otto T, Rübben H (2002) Behandlung von Unfällen im Rahmen der Chemotherapie – Der Essener Chemokoffer. *Notfallmedizin* 8:580-3.
18. Lerner SP, Stein JP und **Goebell PJ** (2000) Molecular Staging of Cancer; Commentary, Case 3. *Cancer Case Presentations: The Tumor Board*, 4:72-6.
19. Schmitz-Dräger BJ, **Goebell P**, Gerharz CD, Schulz WA, Grimm MO, Ebert T (1998) P53 Inaktivierung bei Patienten mit oberflächlichen Harnblasentumoren. In: Bilcher H, Wilbert D (Hrsg.) *Diagnostik und Therapie des Harnblasenkarzinoms*, Eichhorn-Press Verlag, Reinbek.
20. Goretzki PE, **Goebell PJ**, Vogel T, Schnürch HG, Röher HD (1998) Die pelvine Exenteration aus chirurgischer Sicht. *Langenbecks Arch Chir Suppl Kongressbd* 115:246-9.

Zitierfähige Abstracts:

1. **Goebell PJ**, Muller L, Blumenstengel K, Hübner A, Lück A, Vogt M, Marschner N (2013) The German mRCC registry – aims and results after the first 1000 patients. *Eur Urol Supp* 12(1):1106
2. Muller L, **Goebell PJ**, von Verschuer U, Hurtz H-J, Franzem M, Vogt M and Marschner N (2013) Body-mass-index and survival of patients with metastatic renal cell carcinoma: Data from the German prospective RCC Registry. *Eur Urol Supp* 12(1):1102
3. Muller L, **Goebell PJ**, von Verschuer U, Hurtz H-J, Franzem M, Vogt M and Marschner N (2013) Body mass index and survival of patients with metastatic renal cell carcinoma: Data from the German prospective RCC registry. *J Clin Oncol* 31(6):S454

4. Araujo J, Trudel GC, Saad F, Armstrong A, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev V, Efstathiou E, Oudard S, Morris MJ, Sizer B, **Goebell PJ**, de Bono JS, Paliwal P, Durham S, Cheng S and Logothetis C (2013) Overall survival (OS) and safety of dasatinib/docetaxel vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase 3 READY trial. *J Clin Oncol* 31(6):LBA8
5. Rogler AP, **Goebell PJ**, Wullich B, Hartmann A, Stöhr R (2012) Die Rolle von Chromosom 8p-Deletionen und Verlust der sFRP1 Expression beim Urothelkarzinom der Harnblase. *Urologe* 51; S1:12-151.
6. Steiner T, **Goebell PJ**, Kube U, Kindler M, Herrmann E, Janssen J, Schmitz J, Weikert S, Klos S, Steiner G, Jakob A, Staehler M, Overkamp F, Doehn C, Guderian G, Bergmann L (2012) Aktualisierte Ergebnisse einer Nicht-interventionellen Studie mit Everolimus nach Einsatz des ersten VEGFR-TKI. *Urologe* 51; S1:12-151.
7. Eichelberg C, Fischer von Weikersthal L, **Goebell PJ**, Lerchenmuller C, Zimmermann U, Freier W, Schirmacher-Memmel S, Staehler M, Trojan L, De Santis M, Michel MS (2012) Randomisierte, offene Phase III-Sequenzstudie zur Wirksamkeit und Verträglichkeit von Sorafenib (SO) gefolgt von Sunitinib (SU) versus Sunitinib gefolgt von Sorafenib bei Patienten mit fortgeschrittenem/metastasiertem Nierenzellkarzinom (mRCC) ohne vorherige systemische Therapie (SWITCH-Studie) – Ergebnisse einer Sicherheits-Zwischenanalyse. *Urologe* 51; S1:12-151.
8. **Goebell PJ**, Muller L, Blumenstengel K, Hubner A, Luck A, Koska M, Marschner N (2012) Wie behandeln wir Patienten mit metastasiertem Nierenzellkarzinom in Deutschland – update aus dem RCC-Register. *Urologe* 51; S1:12-151.
9. Michel MS, Vervenne WL, **Goebell PJ**, von Weikersthal LF, Freier W, De Santis M, Zimmermann U, Bos MMEMM, Trojan L, Lerchenmuller C, Schenck M, Staehler M, Florcken A, Pahernik S, Los M, von Arkel C, Schirmacher-Memmel S, Eichelberg C (2012) Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): Safety interim analysis results. *J Clin Oncol* 30(15) 4539.
10. Bergmann L, **Goebell PJ**, Kube U, Kindler M, Herrmann E, Janssen J, Schmitz J, Weickert S, Kloos S, Steiner G, Jakob A, Staehler M, Steiner T, Overkamp F, Guderian G, Doehn C (2012) Updated results of a prospective noninterventional study of everolimus after use of 1 VEGFR-TKI. *J Clin Oncol* 30(15)e15044.
11. von Weikersthal LF, Vervenne WL, **Goebell PJ**, Eichelberg C, Freier W, De Santis M, Zimmermann U, Bos MMEMM, Trojan L, Lerchenmuller C, Schenck M, Staehler M, Florcken A, Pahernik S, Los M, von Arkel C, Schirmacher-Memmel S, Michel MS (2012) Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study) – Safety interim analysis results. *Onkologie* 35(S6):237.

12. Bergmann L, **Goebell PJ**, Kube U, Kindler M, Herrmann E, Janssen J, Schmitz J, Weickert S, Kloos S, Steiner G, Jakob A, Staehler M, Steiner T, Overkamp F, Guderian G, Doehn C (2012) Updated results of a prospective non-interventional study of everolimus in Germany after failure of the first VEGFR-TKI in metastatic renal cell carcinoma. *Onkologie* 35(S6):203.
13. **Goebell PJ**, Müller L, Blumenstengel K, Hübner A, Lück A, Koska M, Marschner N (2012) Update aus dem RCC-Register: wie wir Patienten mit metastasiertem Nierenzellkarzinom in Deutschland behandeln. *J Urol Urogynäkol* 19(2):23.
14. Kunath F, Rücker G, Keck B, **Goebell PJ**, Wullich B, Meerpohl JJ (2012) Das Harnblasenkarzinom im Schatten der Nieren- und Prostatakarzinomforschung – Eine Analyse der letzten 10 Jahre. *J Urol Urogynäkol* 19(2):5.
15. Heidenreich A, Albers P, Bokemeyer C, **Goebell PJ**, Gschwend J, Miller K, Müller S, Otremba B, Reuter C, Trojan L, Volkmer B, Wirth M (2012) Cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer previously treated with Docetaxel-containing regimen: Interim analysis on treatment associated side effects resulting from a compassionate-use programme (CUP). *European Urology Supp* 11:E128-U519
16. **Goebell PJ**, Müller L, Blumenstengel K, Hübner A, Lück A, Koska M, Marschner N (2012) How to further solidify data on systemic therapy in metastatic renal cell carcinoma (mRCC) – the German mRCC registry on the treatment reality. *European Urology Supp* 11:E79-U445
17. Jakob A, Kube U, Kindler M, Koepke T, Janssen J, **Goebell PJ**, Schulze M, Schmitz J, Stern S, Overkamp F, Staehler M, Steiner T, Doehn C, Albrecht M, Guderian G, Bergmann L (2011) Results of a pre-planned interim analysis of a non-interventional study of everolimus after failure of the first anti-VEGF therapy in metastatic renal cell carcinoma. *Onkologie* 34; S6:180
18. Müller L, Münch A, **Goebell PJ**, Hübner A, Koska M, Marschner N (2011) Histology, metastases and palliative surgery in mRCC patients. Data from a clinical registry – RCC registry. *Onkologie* 34; S6:182
19. Bergmann L, Kube U, Kindler M, **Goebell PJ**, Jakob A, Steiner T, Staehler M, Overkamp F, Guderian G, Doehn C (2011) Interim analysis of a Non-interventional study of everolimus after failure of the First anti-VEGF therapy. *Eur J Cancer* 47 S1:521
20. Münch A, Müller L, Blumenstengel K, **Goebell PJ**, Hübner A, Hipper A (2010) Das RCC-Register-Zugang zur Behandlungsrealität von Patienten mit metastasiertem Nierenzellkarzinom in Deutschland. *Urologe* 49: S1: 9-146.
21. Keck B, Stoehr R, Becker KF, Lehmann J, Rogler A, Giedl J, **Goebell PJ**, Wullich B, Hartmann A (2010) Loss of E-cadherin in plasmacytoid urothelial Carcinoma (PUC). *Urologe* 49: S1: 9-146.
22. Richterstetter M, Wullich B, Amann K, Häberle L, **Goebell PJ**, Krause FS (2010) Die Wertigkeit der erweiterten TUR-Blase bei der Behandlung von Blasenkarzinomen. *J Urol Urogynäkol* 17:37.
23. Keck B, Stoehr R, Rogler A, Becker KF, **Goebell PJ**, Wach S, Giedl J, Lehmann J, Wullich B, Hartmann A (2010) E-Cadherin-Verlust als Merkmal des plasmazytoiden Urothelkarzinoms (PUC). *J Urol Urogynäkol* 17:36.

24. Legal W, Münch A, Müller L, Blumenstengel K, Lück A, Hipper A, **Goebell PJ** (2010) Die Behandlungsrealität von Patienten mit metastasiertem Nierenzellkarzinom in Deutschland – das RCC-Register. *J Urol Urogynäkol* 17:7.
25. Micka B, Engehausen D, Krot D, Herzing W, Wullich B, **Goebell PJ** (2010) Hat die neoadjuvante Hormontherapie einen Einfluss auf die Risikobeurteilung anhand der Prostatastanzen? *Urologe*, 49:S1,16.
26. Keck B, Stoehr R, Wach S, Löprich E, **Goebell PJ**, Lehmann J, Hartmann A, Wullich B (2009) Histopathologische und klinische Charakterisierung des plasmazytoiden Urothelkarzinoms der Harnblase. *Urologe*, 48:S1,84.
27. Apel H, Walschburger-Zorn K, Pressmar K, **Goebell PJ**, Engehausen DG, Wullich B (2009) Erhöhte Inzidenz maligner Tumoren nach allogener Nierentransplantation: Erlanger Ergebnisse. *Urologe*, 48:S1,26.
28. Legal W, Schrott KM, **Goebell PJ**, Wullich B, Krause FS (2008) Die Prostatastanziobiopsie - Welche Methode ist am zuverlässigsten für die Planung einer nerverhaltenden radikalen Prostatektomie? *Urologe*, 47:S1,47.
29. Fritsche H-M, Burger M, Denzinger S, Otto W, Wieland W, **Goebell PJ**, Wullich B, Hartmann A (2008) Das Plasmazytoide Urothelkarzinom der Harnblase – histologische und klinische Aspekte einer seltenen Tumorentität. *J Urol Urogynäkol* 15:16.
30. **Goebell PJ**, Schmitz-Dräger JR, Schmitz-Dräger BJ (2008), Investigation of Publication Bias using the Model of p53 Accumulation in Bladder Cancer. *J Urol* 179:S4;6.
31. Schenck M, Jäger T, Börgermann C, vom Dorp F, **Goebell PJ**, Rübben H (2007) Standardisierung des Untersuchungsablaufes zur Beurteilung der vesico-urethralen Anastomose nach radikaler retropubischer Prostatektomie (RRP). *Urologe* 46:S1;140.
32. Völler MCW, **Goebell PJ**, Schalken JA (2007) Isolation of prostate stem/progenitor cells using a sphere forming assay. *BJU Int* 100;S3:6-7.
33. **Goebell PJ**, Groshen S, Grossman HB, Waldman F, Cote RJ, Schmitz-Dräger BJ (2007) The International Bladder Cancer Bank - Models for sharing tissue resources. *BJU Int* 100;S3:26-7.
34. Schmitz-Spanke S, **Goebell PJ**, Rübben H, Rettenmeier AW (2007) Zyto- und Genotoxizität von Benzo(a)pyren in primären humanen Urothelzellen. *Arbeitsmed Sozialmed Umweltmed* 42:53.
35. **Goebell PJ**, Mosel F, Rübben H, Rettenmeier AW, Müller G für das Forum Proteomics der Universität Essen (2006) Der kulturelle Nachweis von Harnwegsinfekten – bietet MALDI-TOF Massenspektrometrie eine Alternative ? *Urologe A* 45:S108.
36. Siemer S, van Poppel H, Machtens S, Strohmaier WL, Wechsel HW, **Goebell PJ**, Schmeller N, Oberneder R, Stolzenburg, J-U, Tetens V (2006) Prospektiv randomisierte multizentrische Studie zur Effektivität von TachoSil als Hämostyptikum nach Nierenteilresektion (NT). *Urologe A* 45:S107.
37. Van Poppel H, Siemer S, Lahme S, Altziebler S, Machtens S, Strohmaier W, Wechsel HW, **Goebell PJ**, Schmeller N, Oberneder R, Stolzenburg JU, Becker H, Lüftenegger W, Tetens V,

- Joniau S (2006) Kidney tumour resection with use of tachosil as haemostatic treatment. *Eur Urol* 49:630.
38. Abol-Enein H, Bassi P, Bono AV, Boyer M, Clarke NW, Coppin CML, Cortesi E, **Goebell PJ**, Groshen S, Hall RR, Horwich A, Lehmann J, Malmström PU, Martinez-Piñero JA, Parmar MKB, Roberts JT, Sengeløv L, Sherif A, Stewart LA, Studer U, Sylvester R, Tierney JF, Torti FM, Vale CL, Wallace DMA (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. The Advanced Bladder Cancer Meta-Analysis Collaboration. *Urologe A* 44:S111.
39. **Goebell PJ**, Getzenberg RH, Groshen S, Grossman HB, Cote RJ, Schmitz-Dräger BJ (2005) The phases of marker development: The IBCN consensus view to give molecular discoveries a clinical meaning. *Proc Amer Assoc Cancer Res* 46:LB210.
40. Heim MM, Strumberg D, **Goebell PJ**, Bach F, Hilger RA (2004) LiferLab solution, ein neues Medium für Tumorgewebettransport und Zellkultivierung? *Onkologie* 27:S168.
41. **Goebell PJ**, Rübben H (2004) Rudolf Goebell and his contribution to the surgical management of female stress urinary incontinence. *J. Urol* 171:S323.
42. Chatterjee SJ, Datar R, Youssefzadeh D, George B, **Goebell PJ**, Stein JP, Young L, Shi S-R, Gee C, Groshen S, Skinner DG, Cote RJ (2004) Combined Effects of p53, p21 and pRb Expression in the Progression of Bladder Transitional Cell Carcinoma. *Ann Surg Oncol* 11:636-8.
43. **Goebell PJ**, Schmitz-Dräger BJ, Groshen S and The International Study Initiative on Bladder Cancer (ISBC) (2004) Is p53 immunohistochemistry in superficial bladder cancer of any use ? *Eur Urol Suppl.* 3:238.
44. **Goebell PJ**, Schmitz-Dräger BJ, Groshen S und Heydthausen M (2003). Abschließende Analyse zum prognostischen Wert der P53 Akkumulation beim Harnblasenkarzinom: Die ISBC Studie. *Urologe A* 42:S45.
45. Otto T, Suhr J, **Goebell PJ**, Schmid KW, Rübben H (2003) Survival of patients with high grade superficial bladder tumors (T1G3) treated with transurethral resection (TUR) alone. *J. Urol* 169:A996.
46. **Goebell PJ**, Schmitz-Dräger BJ, Groshen S and Heydthausen M for The International Study Initiative on Bladder Cancer (ISBC) (2003) Do we need P53 immunohistochemistry in superficial bladder cancer ? – Final results of the ISBC combined analysis. *J. Urol* 169:A995.
47. Groshen S, Schmitz-Dräger BJ, Heydthausen M, **Goebell PJ** for The International Study Initiative on Bladder Cancer (ISBC) (2002) On the Use of an Index of Variability for Combining Results of Biomarker Studies - Aspects in The ISBC Combined Analysis on the Prognostic Role of p53 in Bladder Cancer. *Int J Biol Markers* 17:S31.
48. **Goebell PJ**, Schmitz-Dräger BJ, Heydthausen M and Groshen S for The International Study Initiative on Bladder Cancer (ISBC) (2002) The ISBC Combined Analysis. Antigen Retrieval and Choice of Antibodies - *Int J Biol Markers* 17:S30.

49. Björnsson BL, Sylvester R, Getzenberg RH, Oosterlinck W and **Goebell PJ** for the MUND Study Group (2002) Comprehensive Analysis of Urine Markers for Bladder Cancer - The proposed Multicentre Urothelial Neoplasia Detection (MUND) Study. *Int J Biol Markers* 17:S20.
50. George B, **Goebell PJ**, Datar RH, Cai J, Brands FH, Young LL, Shi S-R, Groshen S, Stein JP, Skinner DG, Cote RJ (2002) p21WAF/Cip1, p27Kip1 and p53; expression and impact on clinical outcome in invasive bladder cancer. *Proc Am Soc Clin Oncol* 20:711.
51. **Goebell PJ**, Schmitz-Dräger BJ, Heydthausen M and Groshen S for The International Study Initiative on Bladder Cancer (ISBC) (2002) A critical look at Antigen Retrieval and Choice of Antibodies for p53 Immunohistochemistry - Technical Aspects in the ISBC Combined Analysis. *J. Urol* 167:A453.
52. **Goebell PJ**, Schmitz-Dräger BJ, Heydthausen M und Groshen S für die International Study Initiative on Bladder Cancer (ISBC) (2001) Die ISBC Studie zur p53 Immunhistochemie beim Harnblasenkarzinom: technische Aspekte. *Urologe A* 40:S10.
53. **Goebell PJ**, Groshen S, Heydthausen M und Schmitz-Dräger BJ, The International Study Initiative on Bladder Cancer (ISBC) (2001) The ISBC combined analysis on p53 immunohistochemistry in bladder cancer: an update. *Proceedings of the American Association of Cancer Research* 42:A3108.
54. Schmitz-Dräger BJ, **Goebell P**, Heydthausen M, The International Study Initiative on Bladder Cancer (ISBC) (2000) Update of the ISBC Combined Analysis on P53 Immunohistochemistry in Bladder Cancer. *Eur Urol* 38:511.
55. **Goebell PJ**, Groshen SG, Schmitz-Dräger BJ und Cote RJ (2000) THE INTERNATIONAL BLADDER CANCER BANK - proposal for a new study concept in bladder cancer. *Int J Biol Markers* 15:S22.
56. Anastasiadis AG, Franke KH, Miklosi M, **Goebell P**, Gerharz CD, Schulz WA, Ackermann R (2000) CDK inhibitor p27KIP1 is expressed preferentially in early stage urothelial carcinoma, but does not predict progression. *Eur Urol* 37:A353.
57. Grimm MO, Stapf R, **Goebell P**, Beckmann M, Goretzki P, Schnürch HG, Vögeli TA, Ackermann R (2000) Pelvic exenteration and urinary diversion for extensive or recurrent gynecologic malignancy. *J Urol*:A352.
58. Franke KH, Miklosi M, **Goebell P**, Gerharz CD, Schulz WA, Anastasiadis AG (2000) CDK inhibitor p27KIP1 is expressed preferentially in early stages of urothelial carcinoma, but does not predict progression. *J Cancer Res Clin Oncol* 126:R79.
59. Chatterjee SJ, **Goebell PJ**, Tran QC, Thu S, Datar R, Brands FH, Shi SR, Stein JP, Cote RJ (2000) Effect of p16 expression on pRb phenotype and clinical outcome in patients with invasive bladder cancer. *Proceedings of the American Association of Cancer Research* 41:A43.
60. Schmitz-Dräger BJ, **Goebell PJ**, Heydthausen M, the International Study Initiative on Bladder Cancer (1999) P53 immunohistochemistry and prognosis in bladder cancer: Updated results of the ISBC combined analysis. *Eur Urol* 36:A473.

61. Schmitz-Dräger BJ, **Goebell P**, Heydthausen M, the International Study Initiative on Bladder Cancer (1999) P53 immunohistochemistry as a prognostic marker for bladder cancer: the ISBC combined analysis. *J Urol* 161:A153.
62. The International Study Initiative on Bladder Cancer (ISBC), Schmitz-Dräger BJ, **Goebell P**, Heydthausen M (1999) P53 immunohistochemistry as a prognostic marker for bladder cancer - results of the ISBC metaanalysis. *Eur Urol* 35:A167.
63. Schmitz-Dräger BJ, **Goebell P**, Heydthausen M, The International Study Initiative on Bladder Cancer (ISBC) (1998) p53 Immunohistochemistry as a prognostic marker for bladder cancer - First results of an international metaanalysis. *Eur Urol* 34:A296.
64. Jankevicius F, **Goebell P**, Schulz WA, Ackermann R, Schmitz-Dräger BJ (1998) The value of p21 and p53 overexpression in predicting the outcome after systemic chemotherapy of urothelial cancer. *J Urol* 159:A633.
65. Jankevicius F, **Goebell P**, Kushima M, Meyer O, Schulz W, Ackermann R, Schmitz-Dräger B (1998) The role of p53/p21 phenotypic expression in predicting chemotherapeutic response of urothelial cancer. *Eur Urol* 33:A568.
66. Schmitz-Dräger BJ, **Goebell P**, Bültel H, van Roeyen C, Gerharz CD, Ebert T, Schulz WA (1996) Alterations of MDM2 and P53 in early bladder cancer. *J Urol* 155:A334.
67. Schmitz-Dräger BJ, **Goebell P**, Bültel H, van Roeyen C, Gerharz CD, Grimm MO, Ebert T, Schulz WA (1995) MDM2 and P53 in early bladder cancer. *Urol Res* 23:A276.